Guerbet receives CE mark approval for SeQure and DraKon microcatheters for interventional imaging.
Guerbet, a global specialist in contrast agents and solutions for medical imaging has announced its upcoming European launch of two microcatheters for peripheral embolisation procedures.
The two microcatheters named SeQure and DraKon were obtained as a result of Guerbet’s acquisition of Israeli company Accurate Medical Therapeutics, which was announced in January 2018.
Both of the microcatheters received the CE mark for the delivery of intra-arterial therapy and embolic materials into all peripheral vessels on April 16th 2019.
The SeQure microcatheter is an innovative reflux control microcatheter that uses flow dynamics to create a fluid barrier.
The DraKon is a standard microcatheter adapted for any peripheral embolisations (including conventional trans-arterial chemo-embolisation).
The SeQure and DraKon technologies enhance navigation capabilities for interventional radiologists which as a result enable access to difficult anatomies and the ability to reach further.
Thomas Bonnefont, vice president of commercial interventional imaging said: "Guerbet is expanding its interventional portfolio with new solutions for interventionalists, to further enhance and secure their embolisation cases.
“This new range of microcatheters will allow us to help the interventional radiology community deliver a higher quality of care during image-guided embolisation procedures."
The SeQure and DraKon microcatheters both received FDA clearance on January 26th 2018 and are commercialised on the US market. They are also registered in Hong Kong, New Zealand and Thailand, with a registration plan which includes Australia, China, India, Japan, Korea, Singapore and Vietnam within the next 2 years.
